Back Tuberculosis

AIDS 2012: Isoniazid Preventive Therapy Reduces Risk of TB for HIV+ People on ART

Twelve months of isoniazid (INH) preventive therapy (IPT) significantly reduced the incidence of all tuberculosis (TB) diagnoses among HIV positive people who were taking concurrent antiretroviral therapy (ART) according to results of a large randomized study presented as a late-breaker at the recent XIX International AIDS Conference (AIDS 2012) in Washington, DC.


Read more:

AIDS 2012: Novel PzMA Tuberculosis Combo Shows Potent Activity in Short-term Trial

A triple-combination regimen consisting of the experimental tuberculosis (TB) drug PA-824, the established TB drug pyrazinamide, and the widely used antibiotic moxifloxacin -- dubbed PaMZ -- showed potent bactericidal activity in a randomized 14-day study presented last week at the XIX International AIDS Conference (AIDS 2012) in Washington, DC, and published simultaneously in the July 23, 2012 issue of The Lancet.

Read more:

Janssen Requests FDA Approval of Bedaquiline (TMC207) for Multidrug-resistant TB

Janssen Research & Development this week submitted a New Drug Application requesting U.S. Food and Drug Administration (FDA) accelerated approval of bedaquiline (formerly TMC207), which would be the first drug for difficult-to-treat multidrug-resistant tuberculosis (MDR-TB).

Read more:

Advocates Release Updated Report on Pipeline Drugs for HIV, Hepatitis C, and TB

Drugs are HIV are more effective and plentiful than ever, but in many cases they are not making it into the hands of people who need them, according the 2012 Pipeline Report, released July 21 by HIV i-Base and the Treatment Action Group (TAG). Development of new direct-acting agents for hepatitis C, however, is occurring at a rapid pace.alt

Read more:

Novel Antibiotic Delamanid Is Effective against Multidrug-resistant Tuberculosis

An experimental antibiotic drug, delamanid (OPC-67683), demonstrated good activity against highly-resistant tuberculosis (TB), clearing infection in more than 40% of participants in a Phase 2b trial, researchers reported in the June 7, 2012, New England Journal of Medicine. The drug is currently being studied in HIV positive people taking antiretroviral therapy (ART).

Read more: